{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T23:48:46Z","timestamp":1762040926214,"version":"build-2065373602"},"reference-count":64,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:00:00Z","timestamp":1634169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Taiwan Centers for Disease Control","award":["MOHW108-CDC-C-114-000109","MOHW108-CDC-C-114-000105","MOHW109-CDC-C-114-000105"],"award-info":[{"award-number":["MOHW108-CDC-C-114-000109","MOHW108-CDC-C-114-000105","MOHW109-CDC-C-114-000105"]}]},{"DOI":"10.13039\/100007225","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["MOST 108-2918-I-037-001","109-2823-8-037-002-CV","108-2320-B-037-035-MY3","110-2918-I-037-002","107-2923-B-005-005-MY3"],"award-info":[{"award-number":["MOST 108-2918-I-037-001","109-2823-8-037-002-CV","108-2320-B-037-035-MY3","110-2918-I-037-002","107-2923-B-005-005-MY3"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kaohsiung Medical University Research Center","award":["KMU-TC109B2"],"award-info":[{"award-number":["KMU-TC109B2"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Integrase strand transfer inhibitor (InSTI)-based regimens have become the major first-line treatment for HIV-1-infected patients in Taiwan. Transmitted drug resistance (TDR) and several clinical characteristics are associated with time to virological failure or viral suppression; however, these have not been investigated in Taiwan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine the impact of several factors on treatment outcomes in HIV-1-infected patients in Taiwan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The cohort included 164 HIV-1 treatment-naive patients in Taiwan from 2018 to 2020. Blood specimens were collected to determine the genotypic drug resistance using the Stanford University HIV drug resistance database. Cox proportional hazards models were used to identify factors associated with time to virological failure or viral suppression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The prevalence of TDR in Taiwan was 27.4% and an increasing trend was seen from 2018 to 2020. TDR mutations related to NNRTIs were the most prevalent (21%) while TDR to InSTIs remained at a relatively low level (1.3%). A baseline HIV-1 viral load of \u2265100\u200a000\u2009copies\/mL was associated with a shorter time to virological failure [multivariate hazard ratio (mHR) 7.84; P\u200a=\u200a0.018] and longer time to viral suppression (mHR 0.46; P\u200a&amp;lt;\u200a0.001). Time to viral suppression was shorter in patients receiving InSTI-based regimens (mHR 2.18; P\u200a=\u200a0.006). Different InSTI-based regimens as initial treatment did not affect the treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study found an increasing trend of HIV-1 TDR prevalence from 2018 to 2020 in Taiwan. Baseline HIV-1 viral load and receiving InSTI-based regimens are important factors associated with time to virological failure or viral suppression.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkab361","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T11:11:57Z","timestamp":1631272317000},"page":"185-195","source":"Crossref","is-referenced-by-count":13,"title":["High prevalence of HIV-1 transmitted drug resistance and factors associated with time to virological failure and viral suppression in Taiwan"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-7737","authenticated-orcid":false,"given":"Szu-Wei","family":"Huang","sequence":"first","affiliation":[{"name":"Model Development Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, Frederick, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Chen","family":"Shen","sequence":"additional","affiliation":[{"name":"Center for Tropical Medicine and Infectious Disease, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Hung","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Tropical Medicine and Infectious Disease, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Division of Infectious Disease, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-You","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen-Hsien","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Yin","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hsinchu MacKay Memorial Hospital, Hsinchu, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8006-4917","authenticated-orcid":false,"given":"Po-Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lih-Shinn","family":"Wang","sequence":"additional","affiliation":[{"name":"Section of Infectious Disease, Department of Internal Medicine, Buddhist Tzu Chi General Hospital, Hualien, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Lin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ming Arthur","family":"Chen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Biomedical and Pharmaceutical Science, Fu Jen Catholic University, New Taipei City, Taiwan"},{"name":"Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yuan","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Disease, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"},{"name":"Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[{"name":"Center for Tropical Medicine and Infectious Disease, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Division of Infectious Disease, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Fan","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Tropical Medicine and Infectious Disease, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Medical Laboratory Science and Biotechnology, Kaohsiung Medical University, Kaohsiung, Taiwan"},{"name":"Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"2022021709133449900_dkab361-B1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1468-1293.2008.00561.x","article-title":"The prevalence of transmitted antiretroviral drug resistance in treatment-na\u00efve patients and factors influencing first-line treatment regimen selection","volume":"9","author":"Huang","year":"2008","journal-title":"HIV Med"},{"key":"2022021709133449900_dkab361-B2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"Wittkop","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2022021709133449900_dkab361-B3","doi-asserted-by":"crossref","first-page":"e02411","DOI":"10.1016\/j.heliyon.2019.e02411","article-title":"Surveillance of transmitted HIV drug resistance among newly diagnosed, treatment-naive individuals at a county HIV clinic in Santa Clara County","volume":"5","author":"Chan","year":"2019","journal-title":"Heliyon"},{"key":"2022021709133449900_dkab361-B4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/aid.2017.0295","article-title":"Changes from 2000 to 2009 in the prevalence of HIV-1 containing drug resistance-associated mutations from antiretroviral therapy-naive, HIV-1-infected patients in the United States","volume":"34","author":"Ross","year":"2018","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022021709133449900_dkab361-B5","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/644505","article-title":"Transmission of drug-resistant HIV-1 is stabilizing in Europe","volume":"200","author":"Vercauteren","year":"2009","journal-title":"J Infect Dis"},{"key":"2022021709133449900_dkab361-B6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/QAI.0b013e31817ae5c0","article-title":"Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study","volume":"48","author":"Bannister","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022021709133449900_dkab361-B7","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/QAD.0b013e3282f0b685","article-title":"Transmission of HIV-1 drug resistance in Switzerland: a 10-year molecular epidemiology survey","volume":"21","author":"Yerly","year":"2007","journal-title":"AIDS"},{"key":"2022021709133449900_dkab361-B8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1017\/S0950268817003016","article-title":"Prevalence of transmitted drug resistance among HIV-1 treatment-naive patients in Beijing","volume":"146","author":"Song","year":"2018","journal-title":"Epidemiol Infect"},{"key":"2022021709133449900_dkab361-B9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12879-019-3927-1","article-title":"Diversity of HIV-1 genotypes and high prevalence of pretreatment drug resistance in newly diagnosed HIV-infected patients in Shanghai, China","volume":"19","author":"Wang","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2022021709133449900_dkab361-B10","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/jac\/dkr601","article-title":"Trends of transmitted drug resistance of HIV-1 and its impact on treatment response to first-line antiretroviral therapy in Taiwan","volume":"67","author":"Lai","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1186\/s12879-019-4389-1","article-title":"Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan","volume":"19","author":"Weng","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2022021709133449900_dkab361-B12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/cid\/cir728","article-title":"Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations","volume":"54","author":"von Wyl","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2022021709133449900_dkab361-B13","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/QAI.0b013e3181e544e0","article-title":"HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia","volume":"55","author":"Hamers","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022021709133449900_dkab361-B14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"2022021709133449900_dkab361-B15","first-page":"171","article-title":"Efficacy and tolerability of integrase inhibitors in antiretroviral-naive patients","volume":"17","author":"D\u2019Abbraccio","year":"2015","journal-title":"AIDS Rev"},{"key":"2022021709133449900_dkab361-B16","doi-asserted-by":"crossref","first-page":"106343","DOI":"10.1016\/j.ijantimicag.2021.106343","article-title":"HIV-1 integrase strand transfer inhibitors: a review of current drugs, recent advances and drug resistance","volume":"57","author":"Mbhele","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2022021709133449900_dkab361-B17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2022021709133449900_dkab361-B18","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"2022021709133449900_dkab361-B19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jac\/dkw376","article-title":"Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute\/recent HIV infection","volume":"72","author":"Ambrosioni","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/hiv.12414","article-title":"Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom","volume":"18","author":"Tostevin","year":"2017","journal-title":"HIV Med"},{"key":"2022021709133449900_dkab361-B21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/infdis\/jiw165","article-title":"Successful prevention of transmission of integrase resistance in the Swiss HIV Cohort Study","volume":"214","author":"Scherrer","year":"2016","journal-title":"J Infect Dis"},{"key":"2022021709133449900_dkab361-B22","doi-asserted-by":"crossref","first-page":"35779","DOI":"10.1038\/srep35779","article-title":"Prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in Taiwan","volume":"6","author":"Chang","year":"2016","journal-title":"Sci Rep"},{"key":"2022021709133449900_dkab361-B23","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med"},{"key":"2022021709133449900_dkab361-B24","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"key":"2022021709133449900_dkab361-B25","article-title":"Predictors of virological failure and time to viral suppression of first line integrase inhibitor based antiretroviral treatment","author":"Pyngottu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022021709133449900_dkab361-B26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12879-017-2428-3","article-title":"Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014-July 2015","volume":"17","author":"Bulage","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2022021709133449900_dkab361-B27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/aid.2015.0296","article-title":"Younger age predicts failure to achieve viral suppression and virologic rebound among HIV-1-infected persons in serodiscordant partnerships","volume":"32","author":"Mujugira","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2022021709133449900_dkab361-B28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/cid\/cit003","article-title":"Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009","volume":"56","author":"Hanna","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2022021709133449900_dkab361-B29","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/09540121.2016.1189496","article-title":"Disparities in achieving and sustaining viral suppression among a large cohort of HIV-infected persons in care - Washington, DC","volume":"28","author":"Castel","year":"2016","journal-title":"AIDS Care"},{"key":"2022021709133449900_dkab361-B30","doi-asserted-by":"crossref","first-page":"e13016","DOI":"10.1097\/MD.0000000000013016","article-title":"Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: a retrospective cohort study","volume":"97","author":"Jacobson","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"2022021709133449900_dkab361-B31","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/jac\/dkv284","article-title":"Transmitted drug resistance of HIV-1 strains among individuals attending voluntary counselling and testing in Taiwan","volume":"71","author":"Lai","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.jmii.2014.08.002","article-title":"Prevalence and associated factors for HIV-1 transmitted drug resistance in voluntary clients for counseling and testing in Southern Taiwan","volume":"49","author":"Weng","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"2022021709133449900_dkab361-B33","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1097\/QAD.0000000000000494","article-title":"Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis","volume":"28","author":"Pham","year":"2014","journal-title":"AIDS"},{"key":"2022021709133449900_dkab361-B34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1086\/427212","article-title":"Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy","volume":"40","author":"Novak","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2022021709133449900_dkab361-B35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/jac\/dkaa510","article-title":"Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19","volume":"76","author":"Kao","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B36","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1093\/jac\/dkab159","article-title":"HIV drug resistance among adults initiating antiretroviral therapy in Uganda","volume":"76","author":"Watera","year":"2021","journal-title":"J Antimicrob Chemother"},{"year":"2019","key":"2022021709133449900_dkab361-B37"},{"year":"2017","key":"2022021709133449900_dkab361-B38"},{"key":"2022021709133449900_dkab361-B39","doi-asserted-by":"crossref","first-page":"10747","DOI":"10.1128\/JVI.01827-07","article-title":"Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations","volume":"82","author":"Mitsuya","year":"2008","journal-title":"J Virol"},{"key":"2022021709133449900_dkab361-B40","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/infdis\/jix015","article-title":"Commonly transmitted HIV-1 drug resistance mutations in reverse-transcriptase and protease in antiretroviral treatment-naive patients and response to regimens containing tenofovir disoproxil fumarate or tenofovir alafenamide","volume":"215","author":"Margot","year":"2017","journal-title":"J Infect Dis"},{"key":"2022021709133449900_dkab361-B41","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.04215-14","article-title":"Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors","volume":"59","author":"Basson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021709133449900_dkab361-B42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/jac\/dkt316","article-title":"Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing","volume":"69","author":"Melikian","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B43","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1128\/AAC.44.9.2475-2484.2000","article-title":"Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy","volume":"44","author":"Bacheler","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2022021709133449900_dkab361-B44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/jac\/dkq140","article-title":"Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations","volume":"65","author":"Reuman","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B45","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/nar\/gkg100","article-title":"Human immunodeficiency virus reverse transcriptase and protease sequence database","volume":"31","author":"Rhee","year":"2003","journal-title":"Nucleic Acids Res"},{"key":"2022021709133449900_dkab361-B46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/135965350901400114","article-title":"Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors","volume":"14","author":"Tambuyzer","year":"2009","journal-title":"Antivir Ther"},{"key":"2022021709133449900_dkab361-B47","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/jac\/dkz417","article-title":"Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance","volume":"75","author":"Tzou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/cid\/cit697","article-title":"Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012","volume":"58","author":"Hurt","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2022021709133449900_dkab361-B49","doi-asserted-by":"crossref","first-page":"24927","DOI":"10.18632\/oncotarget.24837","article-title":"HIV-1 integrase strand-transfer inhibitor resistance in southern Taiwan","volume":"9","author":"Tsai","year":"2018","journal-title":"Oncotarget"},{"key":"2022021709133449900_dkab361-B50","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","article-title":"Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies","volume":"360","author":"Egger","year":"2002","journal-title":"Lancet"},{"key":"2022021709133449900_dkab361-B51","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1093\/jac\/dkx300","article-title":"Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen","volume":"72","author":"Raffi","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2022021709133449900_dkab361-B52","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12004","article-title":"Impact of baseline HIV-1 RNA levels on initial highly active antiretroviral therapy outcome: a meta-analysis of 12,370 patients in 21 clinical trials","volume":"14","author":"Stephan","year":"2013","journal-title":"HIV Med"},{"key":"2022021709133449900_dkab361-B53","first-page":"289","article-title":"Why are baseline HIV RNA levels 100,000 copies\/mL or greater associated with mortality after the initiation of antiretroviral therapy?","volume":"38","author":"Wood","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022021709133449900_dkab361-B54","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1086\/379201","article-title":"Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy","volume":"188","author":"Wood","year":"2003","journal-title":"J Infect Dis"},{"key":"2022021709133449900_dkab361-B55","doi-asserted-by":"crossref","first-page":"32947","DOI":"10.1038\/srep32947","article-title":"Rapid HIV viral load suppression in those initiating antiretroviral therapy at first visit after HIV diagnosis","volume":"6","author":"Hoenigl","year":"2016","journal-title":"Sci Rep"},{"key":"2022021709133449900_dkab361-B56","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","article-title":"Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial","volume":"374","author":"Lennox","year":"2009","journal-title":"Lancet"},{"key":"2022021709133449900_dkab361-B57","doi-asserted-by":"crossref","first-page":"603068","DOI":"10.3389\/fphar.2021.603068","article-title":"Three-drug regimens containing integrase inhibitor show good efficacy and safety in treatment-naive patients with HIV-1: a Bayesian analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2022021709133449900_dkab361-B58","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00126334-200112010-00002","article-title":"Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy","volume":"28","author":"Skowron","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022021709133449900_dkab361-B59","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S2055-6640(20)30037-6","article-title":"Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV","volume":"5","author":"Stirrup","year":"2019","journal-title":"J Virus Erad"},{"key":"2022021709133449900_dkab361-B60","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1001\/archinte.162.18.2125","article-title":"Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects","volume":"162","author":"De Luca","year":"2002","journal-title":"Arch Intern Med"},{"key":"2022021709133449900_dkab361-B61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1089\/apc.2015.0040","article-title":"Differences in response to antiretroviral therapy by sex and hepatitis C infection status","volume":"29","author":"Marcus","year":"2015","journal-title":"AIDS Patient Care STDS"},{"key":"2022021709133449900_dkab361-B62","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s10461-016-1297-x","article-title":"Psychiatric distress, drug use, and HIV viral load suppression in Russia","volume":"20","author":"Ustinov","year":"2016","journal-title":"AIDS Behav"},{"key":"2022021709133449900_dkab361-B63","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/QAI.0b013e31826cc592","article-title":"Patterns of adherence to raltegravir-based regimens and the risk of virological failure among HIV-infected patients: the RALTECAPS cohort study","volume":"61","author":"Gras","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2022021709133449900_dkab361-B64","doi-asserted-by":"crossref","first-page":"e114441","DOI":"10.1371\/journal.pone.0114441","article-title":"Patients infected with CRF07_BC have significantly lower viral loads than patients with HIV-1 subtype B: mechanism and impact on disease progression","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/1\/185\/42543419\/dkab361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/1\/185\/42543419\/dkab361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T23:37:51Z","timestamp":1673221071000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/1\/185\/6397013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,14]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,10,14]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab361","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,10,14]]}}}